Janssen gets OK for Concerta XL in UK
J&J subsidiary Janssen-Cilag has been granted approval in the UK for itsnew 12-hour treatment for attention-deficit hyperactivity, Concerta XL (methylphenidate HCl). The product is the first once-daily treatment for ADHD to be approved in the UK, which is acting as reference member state for pan-European Union registration, and eliminates the need for children to receive medication during or after school hours.
The product was approved under the Concerta brand name in the USA last year, and has put in a strong showing in that market, becoming the most widely-prescribed methylphenidate extended-release formulation there, according to Janssen-Cilag.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze